在重症监护中使用的药物对常规凝血检测的影响
Joffrey Feriel1, Marjorie A Goujon1, Miki Desez1
1Clinical Development-Medical Affairs Department, Diagnostica Stago, 3 allée Thérésa, 92600 Asnieres sur Seine, France.
Diagnostics (Basel, Switzerland)
|April 12, 2025
概括
接受某些药物的重症患者可能会因药物相互作用而经历改变的凝血测试结果. 本综述详细介绍了氧巴胺和普罗波等药物如何影响凝血试验,影响ICU中的患者管理.
科学领域:
- 临床化学 临床化学
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
背景情况:
- 凝血检测在ICU中对于管理血液静止,评估出血风险和指导治疗至关重要.
- 在重症监护中使用的许多药物可以干扰凝血试验,无论是体外还是体外.
- 缺乏对这些药物干扰对凝血试验的综合性审查.
研究的目的:
- 对药物干扰与常见凝血试验的文献进行批判性分析.
- 确定特定药物对染色体和计时测定的影响.
- 概述这些干扰对ICU患者管理的影响.
主要方法:
- 文献审查和批判分析.
- 药物影响凝血试验的药物的鉴定.
- 干扰的分类为体外或体外效应.
主要成果:
- 氧巴胺,脂质乳液,和propofol影响色素测定.
- 基化化合物,艾米齐祖马布,rFVIIa,抗生素和sugammadex会影响时间计测试.
- N-乙半氨酸,SSRI和特拉马多尔会影响血液静止系统,这对抗凝血管理构成了挑战.
结论:
- 药物干扰凝血试验在ICU中很常见,并可能影响患者管理.
- 了解这些相互作用对于准确解释凝血试验至关重要.
- 可能需要进一步的研究来澄清具体的机制和临床影响.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
552
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
552
Disorders of Hemostasis
656
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
656
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
405
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
405
Drug Concentrations: Measurements
291
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
291
Therapeutic Index
4.0K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.0K


